دورية أكاديمية

The Hydrolysis of the Prostaglandin Analog Prodrug Bimatoprost to 17-Phenyl-trinor PGF[sub 2α] by Human and Rabbit Ocular Tissue.

التفاصيل البيبلوغرافية
العنوان: The Hydrolysis of the Prostaglandin Analog Prodrug Bimatoprost to 17-Phenyl-trinor PGF[sub 2α] by Human and Rabbit Ocular Tissue.
المؤلفون: Hellberg, Mark R., Ke, Tai-Lee, Haggard, Karen, Klimko, Peter G., Dean, Tom R., Graff, Gustav
المصدر: Journal of Ocular Pharmacology & Therapeutics; Apr2003, Vol. 19 Issue 2, p97-103, 7p
مصطلحات موضوعية: PROSTAGLANDINS, DRUGS, HYDROLYSIS, PHARMACOLOGY
مستخلص: Bimatoprost (Lumigan™), the ethyl amide derivative of the potent prostaglandin FP agonist 17-phenyl-trinor PGF[sub 2α], has been reported to be a member of a pharmacologically unique class of ocular hypotensive agents. To confirm that bimatoprost, which is intrinsically active as an FP prostaglandin agonist, is also a prostaglandin analog prodrug, the hydrolysis of bimatoprost by ocular tissues was studied by incubating solutions containing bimatoprost with either human or rabbit ocular tissue. The ethyl amide group of bimatoprost was hydrolyzed by rabbit and human cornea, iris/ciliary body and Thasclera to produce the expected carboxylic acid product, 17-phenyl-trinor PGF[sub 2α]. The rate of hydrolysis by human and rabbit cornea and iris/ciliary body is similar, whereas the rate of hydrolysis by the sclera is slower in humans than in rabbits. These studies show that human and rabbit ocular tissue (cornea, iris/ciliary body and sclera) can convert bimatoprost to the potent prostaglandin FP agonist 17-phenyl-trinor PGF[sub 2α]. Separate in vitro studies clearly show that both bimatoprost and 17-phenyl-trinor PGF[sub 2α] have affinity for and are agonists at the human FP receptor. Taken together, the data strongly suggests that the ocular hypotensive effect of bimatoprost can be attributed to its activity as a prostaglandin receptor agonist either directly or through its role as a prostaglandin agonist prodrug. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Ocular Pharmacology & Therapeutics is the property of Mary Ann Liebert, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10807683
DOI:10.1089/108076803321637627